Tissue-Engineered Construct Based on Amniotic Membrane and Calcium Alginate for Cesarean Section Wound Healing

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorAsfendiyarov Kazakh National Medical University

About this trial

This clinical trial aims to evaluate the safety and efficacy of an experimental tissue-engineered construct (TEC) based on amniotic membrane and calcium alginate for promoting epithelialization and improving scar quality in patients after cesarean section. The study will assess both biological and clinical indicators of wound healing, including cytokine dynamics (IL-6, IL-10), ultrasound characteristics, and patient-reported outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women aged 18 years and older.

Planned elective cesarean section for medical indications (breech presentation, multiple pregnancy, large fetus, uterine scar, etc.).

Absence of severe obstetric complications (e.g., preeclampsia, hemorrhage, placental abruption).

No decompensated chronic diseases or acute infections.

Disqualifiers

Acute infectious, autoimmune, or oncological diseases.

Severe pregnancy complications (preeclampsia, eclampsia, decompensated gestational diabetes).

Emergency cesarean section.

Severe postpartum complications: massive bleeding (>1000 mL), infection, abscess, severe anemia, allergic reactions to dressing materials.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Tissue-engineered construct based on amniotic membrane and calcium alginate (TEC)

    Device

    Application of a bioresorbable tissue-engineered construct (based on amniotic membrane and calcium alginate) on the postoperative skin incision site to promote epithelialization and improve scar healing.

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: Tissue-Engineered Construct (Amniotic Membrane + Calcium Alginate)Experimental treatment 1 intervention
Group B: Standard Postoperative CareNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Serum interleukin-6 (IL-6), interleukin-10 (IL-10) concentration

Dynamic evaluation of systemic inflammatory response; IL-6, 10 levels measured by ELISA in peripheral blood.

Time frame
Preoperative baseline, Day 3, Day 28

Secondary outcomes

1

POSAS clinical scar assessment (Observer and Patient Scale)

Clinical evaluation of scar healing using the Patient and Observer Scar Assessment Scale (POSAS), including vascularity, pigmentation, thickness, relief, and pliability. Both patient and clinician assessments collected.

Time frame
Day 5-7, Day 28
2

Ultrasound-assessed scar thickness and echogenicity

Quantitative ultrasound assessment of postoperative scar (thickness, echogenicity, and vascularization) using Doppler imaging.

Time frame
Day 3, Day 28
3

Cosmetic and photographic scar assessment

Remote follow-up with voluntary photographic documentation and patient self-assessment of cosmetic outcomes (color, relief, discomfort, satisfaction).

Time frame
Week 12

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Asfendiyarov Kazakh National Medical University

Lead sponsor

Center for Perinatology and Pediatric Surgery, Almaty, Kazakhstan

Collaborator

Zhalyn Scientific and Technical Production Center, Almaty, Kazakhstan

Collaborator